Full Press Release Details
Applied DNA Announces Selected Preliminary
Unaudited Fiscal Fourth Quarter and Year End Results
STONY BROOK, N.Y. - December 15,
2017 - Applied DNA Sciences, Inc. (NASDAQ: APDN; "Applied DNA) today announced selected preliminary unaudited financial results
for the full fiscal year and quarter ended September 30, 2017.
Preliminary (Unaudited) Fiscal 2017 Financial Results:
Preliminary (Unaudited) Fiscal Fourth
The Company also announced that it anticipates
filing its Annual Report on Form 10-K for the fiscal year ended September 30, 2017 with the Securities and Exchange Commission
by December 29, 2017.
"Our fiscal 2017 performance reflects
growing market awareness and adoption of our DNA technology platform in our key business verticals, resulting in the largest pipeline
of pilot projects and highest annual recurring revenue run-rate in Applied DNA's history," stated Dr. James Hayward,
president and CEO. "In addition to seeing increasing long-term demand in our textile business, we have broadened the applicability
of our technology platform in markets adjacent to our core markets and are successfully demonstrating to manufacturers that molecular
tag technology can be strategic to their business goals. This is yielding partnerships with market leaders such as Videojet in
inkjet printing and marking systems and Rosier in fertilizer that accelerates our time-to-revenue in their respective verticals.
We believe that our successes in fiscal 2017 place us firmly on a path to revenue growth in fiscal 2018."
The financial data contained in this press release are unaudited,
preliminary, based upon Applied DNA's good faith estimates and subject to completion of Applied DNA's financial closing procedures.
While Applied DNA expects that its final financial results for the fiscal year and quarter ended September 30, 2017, following
the completion of its financial closing procedures, will generally be consistent with the amounts provided in this press release,
Applied DNA's actual results may differ materially from these estimates as a result of the completion of its financial closing
procedures, as well as final adjustments and other developments that may arise between now and the time that its financial results
for the fiscal year and quarter ended September 30, 2017 are finalized.
The results provided in this press release are preliminary and subject
to completion and audit of Applied DNA's financial statements in conjunction with the Company's 2017 Form 10-K filing
with the Securities and Exchange Commission anticipated to occur by December 29, 2017.
About Applied DNA Sciences
Go to adnas.com for more information, events and to learn
more about how Applied DNA Sciences makes life real and safe. Applied DNA's Common stock is quoted on NASDAQ under the
symbol APDN, and its warrants are quoted under the symbol APDNW.
Forward-Looking Statements
The statements made by APDN
in this press release may be "forward-looking" in nature within the meaning of the Private Securities Litigation Act
of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based
on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could
differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance, market
competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual
Report on Form 10-K filed on December 6, 2016, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2017, May
11, 2017 and August 10, 2017 which are available at www.sec.gov. APDN undertakes no obligation to update publicly
any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence
of unanticipated events, unless otherwise required by law.
Investor contact: Sanjay M. Hurry, 212-838-3777, LHA, shurry@lhai.com
Media contact: Susan Forman, Dian Griesel Int'l., 212-825-3210,